J&J Consumer Business Expansion On Table After Consent Decree Obligations End
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J is “very excited about the possibility of consumer becoming a bigger part of our business,” CFO Caruso says, noting it hopes to grow the business organically and through acquisitions. But J&J first must complete its obligations under a consent decree related to manufacturing quality problems.
You may also be interested in...
Tylenol Relaunch Ads Harken To “Trusted” History
In online video ads for Tylenol, the firm says “for everything we do, we know you do so much more.” CFO Dominic Caruso says the ad campaign will reconnect the brand with consumers.
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.